NCT05784961Not yet recruiting
Impact of tDCS on Cannabis Craving in Schizophrenia
Impact of tDCS on Cannabis Craving in Patients With Schizophrenia and Cannabis Use Disorder: A Randomized, Double-Blind, Placebo-Controlled, Multi-Center Study
Source: ClinicalTrials.gov · Last updated 16 Feb 2024 · Not updated for over 12 months - ask the site whether it is still open
Brief summary (registry, in English)
This study aims to evaluate the tDCS's impact on cannabis craving in patients with schizophrenia and cannabis addiction disorder.
- Status (registry)
- Not yet recruiting
- Study type
- Interventional
- Enrollment
- 138 (estimated)
- First submitted
- 17 Oct 2021
- Start date
- 1 Mar 2024
- Primary completion date
- 1 Mar 2027
- Lead sponsor
- Centre hospitalier de Ville-Evrard, France
- Diseases
- Schizophrenia
- NCT number
- NCT05784961
What you commit to
- Study type: Interventional
- Planned participants: 138
- From 1 Mar 2024 to the primary completion date, 1 Mar 2027
- 2 sites in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Other illness
- Presence of any other psychiatric disorder, as per DSM-5 criteria.
- Contraindications to tDCS (presence of intracranial metal material, intracranial hypertension, etc.).
Other
- Pregnancy, possible pregnancy due to lack of contraception, breastfeeding.
- Currently active suicidal or self-injurious ideation (suicidal or not)
- Patients with Serious medical codition
- Other "moderate" to "severe" addictions, according to DSM 5 criteria (excluding tobacco and coffee).
- Subjects already treated by tDCS
- Patients under legal guardianship (except under curatorship)
- Patients under safeguard of justice
Who the study is looking for
- Patients (male or female) aged 18-65
- Patients with schizophrenia according to DSM 5 criteria with Comorbid diagnosis of "cannabis use disorder"
- Stabilized patients: total score = 80 at initial PANSS score and = 3 at the following PANSS points:
- conceptual disorganization
- distrust
- hallucinatory behaviour
- Unusual content of thought
- Patients without any other drug or psychotherapeutic treatment for cannabis dependence ("naive" patients)
- Reported cannabis use greater than three times per week in the past three years
- Signed consent to participate in research
- Affiliation to a French social security scheme
- Patient fluent in the French language
Age in the registry: 18 years to 65 years · Sex: All · Does not accept healthy volunteers
Sites (2)
Sites in registry order. Save your city in your profile to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Youcef Bencherif Coordinator of this site? Confirm its status | Neuilly-sur-Marne | France | Unknown status |
| Ch Ville Evrard Coordinator of this site? Confirm its status | Neuilly-sur-Marne | France | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.